Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier for AAV9 Delivery in a Mouse Model of Huntington's Disease.
Huntington’s disease
blood–brain barrier opening
focused ultrasound
gene therapy
microbubbles
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
19
04
2024
revised:
17
05
2024
accepted:
20
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Huntington's disease (HD) is a monogenic neurodegenerative disorder caused by a cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the
Identifiants
pubmed: 38931834
pii: pharmaceutics16060710
doi: 10.3390/pharmaceutics16060710
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : R01NS123557
Pays : United States
Organisme : Brigham Research Institute
ID : N/A
Organisme : Hereditary Disease Foundation
ID : N/A